Navigation Links
BT Pushes for R&D Innovation at Bio-IT World Conference
Date:4/14/2011

BOSTON, April 14, 2011 /PRNewswire/ -- BT (NYSE: BT) shared its vision of the future of pharma R&D and the application of cloud computing strategies to pharma research at the Bio-IT World Conference & Expo held this week in Boston. This vision reflects BT's strong capabilities and increasing specialization around a number of industry sectors. Many of the world's leading pharmaceutical companies rely on BT to support their strategy in terms of globalization, operational effectiveness and innovation cycles.

In a keynote panel session, Yury Rozenman, Global Head of Marketing, Pharmaceutical and Life Sciences Sector, BT Global Services, described the pressures currently facing pharma R&D, as well as the opportunities to improve the R&D and innovation process by seamlessly connecting partners, suppliers, biotechs, devices and diagnostic, regulatory agencies and clinical research organizations in an R&D ecosystem.

Rozenman said: "An R&D innovation ecosystem is essentially a networked cooperative: the more participants, the greater value; the more contribution by individual participants, the less expense to use the ecosystem."

Rozenman noted that the benefits of embracing the R&D innovation ecosystem model include increased speed to trial, leading to savings of millions of dollars per drug, reduced costs via out-tasking, and more effective collaboration between industry players and partners, leading to improved research productivity. The differentiator is the ability to integrate not just data and applications but the human resources of the global R&D pharma community.

Leading a session on cloud computing at the same event, Neil Lock, IT Services Program Director, BT Global Services, examined the practical aspects of cloud computing as it relates to pharma R&D.

Lock said: "Much of the debate, hype and headlines about cloud computing focuses on technology rather than benefits.  And frankly, many are suffering from cloud fatigue.  Pharma organizations want to realize the benefits of cloud computing, but they first need to get beyond the fog of confusion surrounding cloud terminology, focus on deliverable business results and look at what they really have to do to make cloud solutions work for them."

Lock offered real-world examples of how migrating to cloud applications has led to greater flexibility, more reliable services, reduced financial risk, and lower costs.  Lock also discussed the evolution to "smart communities," which describes the way in which customers, software vendors and service providers need to work together and collaborate to deliver real value from IT Investments made.

Bas Burger, President, Global Commerce, BT Global Services said: "The vision we shared this week in Boston demonstrates how the R&D efforts of pharmaceutical companies can benefit from BT's industry focused assets in product portfolio, solution designs and infrastructure as well as from our sector-specific customer management and service teams. By focusing on the pharmaceutical sector's unique needs, and offering customers access to teams with decades of experience solving problems in their sector, BT is seen as a reliable partner. This is about specialist people, portfolio and intellectual property, embedded throughout our business. Our customers can leverage many of our market leading assets. We have been serving some of the world's biggest brands in this industry for many years, and have a track record of helping them thrive."

About BT

BT is one of the world's leading providers of communications solutions and services operating in more than 170 countries.  Its principal activities include the provision of networked IT services globally; local, national and international telecommunications services to our customers for use at home, at work and on the move; broadband and internet products and services and converged fixed/mobile products and services.  BT consists principally of four lines of business: BT Global Services, Openreach, BT Retail and BT Wholesale.

In the year ended 31 March 2010, BT Group's revenue was 20,911 million pounds.

British Telecommunications plc (BT) is a wholly-owned subsidiary of BT Group plc and encompasses virtually all businesses and assets of the BT Group.  BT Group plc is listed on stock exchanges in London and New York.

For more information, visit www.bt.com/aboutbt


'/>"/>
SOURCE BT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections
2. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
3. LOREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip
4. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
5. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
6. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
7. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
8. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
9. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
10. Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International
11. Pfizer Inc and GoIndustry DoveBid Partner to Auction Surplus Equipment from R&D Facilities Across the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Dining at the University of California Berkeley, and other leading institutions in announcing ... buying power of institutions to change the way animals are raised for food. ...
Breaking Medicine News(10 mins):